THERAPY DOSSIER · th-f1778d89def3

Corticotropin-releasing hormone receptor 2 (CRHR2) antagonist

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26597886 ↗2015Reported harm

Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis.

MouseChemical/toxinICR background and CRHR2 knockout miceMaleIntracolonic injectionAfter DSS-induced colitis, during the healing phase

Model: Dextran sodium sulfate induced colitis, studied during the mucosal healing phase after DSS withdrawal

CRHR2 antagonism after DSS colitis increased disease activity, delayed healing, reduced epithelial proliferation and increased apoptosis and proinflammatory cytokine expression, and CRHR2 knockout mice showed increased mortality, supporting CRHR2 activation rather than blockade as the repair-promot…

Extraction: extract · Supplied extraction confidence: 0.4. Machine-extracted fields require source verification.

Loading the evidence…